• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Temporal trends of case-fatality in patients undergoing dual-injection coronary chronic total occlusion recanalization
ConclusionAnnual number of CTO procedures performed in Germany increased from 2009 to 2020 with a concomitant anti-proportional decrease in the case-fatality. Our findings may help to draw more attention to predictors of in-hospital case fatality in patients hospitalized for CTO recanalization.Graphical abstract
Source: Clinical Research in Cardiology - September 11, 2023 Category: Cardiology Source Type: research

A meta-analysis evaluating efficacy and safety of colchicine for prevention of major cardiovascular events in patients with coronary artery disease
ConclusionsColchicine is an effective, relatively safe drug that could be considered for the treatment of CAD. However, we need to pay attention to the increasing occurrence of non-cardiovascular mortality and infection especially pneumonia possibly caused by colchicine.Graphical abstractEfficacy and safety of colchicine for patients with CAD.CAD coronary artery disease;RCTs randomized controlled trials;OR odds ratio;MACEs major adverse cardiovascular events;ACS acute coronary syndrome;NNT number needed to treat;NNH number needed to harm
Source: Clinical Research in Cardiology - July 28, 2023 Category: Cardiology Source Type: research

Patients with higher-atherothrombotic risk vs. lower-atherothrombotic risk undergoing coronary intervention with newer-generation drug-eluting stents: an analysis from the randomized BIOFLOW trials
ConclusionIn the era of newer-generation DES, patients with H-ATR still are at hazard for ischemic events. Patients with BP-SES had lower TLF rates as compared with DP-EES, most consistent in L-ATR whereas in H-ATR patients most probably secondary preventive strategies are of higher value.Clinical trial registrationClinicaltrial.gov. NCT01356888, NCT01939249, NCT02389946.https://clinicaltrials.gov/show/NCT01356888,https://clinicaltrials.gov/show/NCT01939249,https://clinicaltrials.gov/show/NCT02389946.Graphical abstract
Source: Clinical Research in Cardiology - April 16, 2023 Category: Cardiology Source Type: research

Contemporary incidence and predictors of left ventricular thrombus in patients with anterior acute myocardial infarction
ConclusionsThe risk of LVT after anterior AMI with new-onset wall motion abnormalities is low, but this complication remains present in the contemporary era of timely pPCI and potent  dual antiplatelet therapy .
Source: Clinical Research in Cardiology - January 18, 2023 Category: Cardiology Source Type: research

Clonal hematopoiesis of indeterminate potential in patients with acute coronary syndrome undergoing percutaneous coronary intervention in the absence of traditional risk factors
ConclusionThe most frequent CHIP-related mutations,DNMT3A, TET2, andASXL1 are significantly associated with increased risk of recurrent cardiovascular events. Our study may be valuable target to reduce residual risk in patients with ACS carrying specific mutations.Graphical abstract
Source: Clinical Research in Cardiology - June 15, 2022 Category: Cardiology Source Type: research

Ten-year all-cause death following percutaneous or surgical revascularization in patients with prior cerebrovascular disease: insights from the SYNTAX Extended Survival study
ConclusionPrior CEVD was associated with a significantly increased risk of 10  year all-cause death which was similar in patients treated with PCI or CABG. These results do not support preferential referral for PCI rather than CABG in patients with prior CEVD.Trial registration: SYNTAX: ClinicalTrials.gov reference: NCT00114972. SYNTAX Extended Survival: ClinicalTrials.gov reference: NCT03417050.Graphic abstract
Source: Clinical Research in Cardiology - October 1, 2021 Category: Cardiology Source Type: research

Clinical risk predictors in atrial fibrillation patients following successful coronary stenting: ENTRUST-AF PCI sub-analysis
ConclusionAfter PCI in AF patients, increasing CHA2DS2-VASc score was associated with increased bleeding rates and CHA2DS2-VASc score ( ≥ 5) predicted the occurrence of stent thrombosis. Paroxysmal AF was associated with MI. These findings may have important clinical implications in AF patients.
Source: Clinical Research in Cardiology - October 24, 2020 Category: Cardiology Source Type: research

Anti-thrombotic strategies in patients with atrial fibrillation undergoing PCI
AbstractTriple anti-thrombotic therapy combining oral anticoagulation and dual anti-platelet therapy following percutaneous coronary intervention in patients with atrial fibrillation was considered as standard and recommended by guidelines. While bleeding risk is considerable with that approach, data for efficacy are scare. Several trials assessed the possibility of reducing anti-thrombotic treatment by mainly shortening the exposure to acetylsalicylic acid. Dropping one of the anti-platelet components might increase the risk of stent thrombosis, myocardial infarction or stroke. Despite that fear, the recent trials ’ pri...
Source: Clinical Research in Cardiology - July 20, 2020 Category: Cardiology Source Type: research

Impact of renal function on clinical outcomes after PCI in ACS and stable CAD patients treated with ticagrelor: a prespecified analysis of the GLOBAL LEADERS randomized clinical trial
ConclusionsIRF negatively impacted long-term prognosis after PCI. There were no differential treatment effects found with regard to all-cause death or new Q-wave MI after PCI in patients with IRF treated with ticagrelor monotherapy.Clinical trial registrationThe trial has been registered with ClinicalTrials.gov, number NCT01813435.Graphic abstract
Source: Clinical Research in Cardiology - January 9, 2020 Category: Cardiology Source Type: research

Pages: 1  2